Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Wynn Resorts, Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.86 (market cap $868.62M), while Wynn Resorts, Limited trades at $104.25 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 12.4× Amphastar Pharmaceuticals Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WYNN | |
|---|---|---|
Market Cap | $868.62M | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $133.34 |
52-Week Low | $16.87 | $94.37 |
Enterprise Value | $1.27B | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.86, down 2.22% today, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
Outlook is cautious due to recent earnings misses and regulatory scrutiny, including an FDA warning letter. Analyst consensus leans Hold (66.67%) with limited Buy support. Key risks include competitive pressures and potential tariff impacts on generic drugs. Cash flow trends improved in 2026 with net cash flow rising to $36 million.
Wynn Resorts (WYNN) trades at $104.59, up 2.04% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, driven by Macau performance, though U.S. margins face pressure. The company maintains solid revenue growth but carries high debt levels, with net cash flow negative due to significant capital expenditures for expansion projects like Wynn Al Marjan.
The outlook is cautiously optimistic, with a consensus price target of $133 offering ~27% upside. Key opportunities include Macau recovery and new project growth, while risks involve high leverage, rising capex, and regional economic sensitivity. Investors should weigh strong institutional support against execution risks in upcoming expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
